Developing a patient-derived bladder cancer organoid biobank suitable for large-scale drug screenings

Bladder cancer (BC) has the highest recurrence rate of any known cancer, ranging from 30% to 70%, with rates of progression as high as 10% to 30% for high-risk tumors, therefore there is an urgent need to develop novel and more effective therapies that can provide patient benefit.

The lack of research funding in this area has limited the development of novel therapies for bladder cancer which has not significantly improved over the past 30 years. Therefore, there is a compelling need for the industry to carry out high-quality, patient-oriented precision medicine studies using clinically relevant models amenable to large-scale drug screenings.

Download our poster to discover:

• The establishment of a rich BC organoid biobank consisting of 50 patient-derived models of varying tumor stages, age, and gender
• The key clinical and molecular characteristics of the BC biobank
• The optimization of an automated large-scale drug screening setup - specially designed to produce quick readouts of potency and toxicity for a large library of compounds